IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase II trial revealed that felzartamab, an ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an ...

Overall, administration of felzartamab was generally well tolerated ... need for additional treatments to address high-risk IgA nephropathy,” said Uptal Patel, M.D., Head of Development, HI ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

A top ERA abstract presents a biomarker-based model that non-invasively estimates kidney fibrosis in patients with IgA ...

Panelists discuss how step-therapy for immunoglobulin A (IgA) nephropathy is evolving toward a more personalized approach, ...

Immunoglobulin A (IgA) nephropathy is a condition that causes a certain type of protein to build up in your kidneys. It progresses differently in everyone. Your kidneys might still work well years ...

IgA nephropathy is the leading cause of kidney failure. Around half of those with IgA nephropathy will see worsening kidney function over many years. For some people, this happens more quickly.

“This is promising news for patients and supports the potential of felzartamab to be a meaningful treatment option for people living with IgA nephropathy, a leading cause of chronic kidney disease.